Intech Investment Management 13F: Cuts CAH Stake by $15M

Intech Investment Management Trims Holdings in Cardinal Health

Intech Investment Management reduced its position in Cardinal Health, Inc. NYSE CAH by 29.9% during the period ended May 8, 2026, according to a Form 13F filed with the Securities and Exchange Commission. The fund cut 62,358 shares of the medical distributor, leaving it with 146,183 shares. The remaining stake carried a reported market value of approximately $34.7 million based on the filing details.

Details of the Reduction

Prior to this adjustment, Intech Investment Management held 208,541 shares of Cardinal Health. The reduction of 62,358 shares lowered the firm's total exposure significantly during the reporting period. This backward-looking filing captures holdings as of May 8, 2026, and does not necessarily reflect the fund's current holdings today.

Cardinal Health Stock Performance and Valuation

Cardinal Health shares trade around $237.56 on the New York Stock Exchange. The stock has experienced a wide trading band over the past year, moving between a 52-week low of $145.87 and a peak of $258.30. With a market capitalization of $52.5 billion, the company trades at a trailing price-to-earnings ratio of 31.2, while its forward P/E sits at 16.0.

Recent Earnings Results

For its financial performance, Cardinal Health reported annual revenue of $254.2 billion alongside a revenue growth rate of 5.8%. The company generated a net margin of 0.67% and a return on equity reflecting its operational scale in the healthcare distribution sector.

Dividend Payments

Cardinal Health returns capital to shareholders via an annual dividend rate of $2.06 per share, yielding 0.92%. The payout ratio stands at 28.3%, indicating that less than a third of earnings go toward meeting dividend obligations.

Wall Street Analyst Coverage

Wall Street firms remain generally positive on Cardinal Health, which holds a consensus recommendation of strong buy across 16 analyst opinions. On August 12, 2026, Citigroup maintained its buy rating and raised its target from $265.00 to $280.00. The following day, Barclays kept its overweight rating and lifted its target to $275.00 from $258.00. TD Cowen also maintained a buy rating on August 13, 2026, raising its target from $275.00 to $280.00, while JP Morgan maintained a neutral rating with a target moved to $260.00 from $215.00. Later, RBC Capital initiated coverage on August 19, 2026, with an outperform rating and a $276.00 price target. More recently, UBS maintained a buy rating on October 16, 2026, while lifting its price target from $280.00 to $295.00. The overall average price target rests at $270.94.

Inside Cardinal Health's Operations

Headquartered in Dublin, Ohio, Cardinal Health operates as a major healthcare services and products company supporting hospitals, pharmacies, clinical laboratories, and surgery centers. The business handles the distribution of branded and generic pharmaceuticals alongside medical and surgical products. It employs nearly 58,800 people globally to manage supply chains and specialty healthcare delivery.

What to Watch at Cardinal Health, Inc.

Investors monitoring Cardinal Health should keep an eye on upcoming regulatory disclosures and the company's next quarterly earnings report scheduled for November 5, 2026. Institutional filing updates from other major asset managers will offer further clarity on how large funds are adjusting their healthcare allocations.